中药复方治疗肝硬化腹水临床研究进展
Clinical Research Progress of Traditional Chinese Medicine Compound in the Treatment of Liver Cirrhosis Ascites

肝硬化是各种慢性肝病的终末期，以感染乙型肝炎病毒(Hepatitis B virus)常见，据统计全球感染HBV人数达2.57亿，而腹水是肝硬化的常见并发症，预示着肝硬化进展为失代偿期，其临床预后不佳，3年内死亡率达50%。腹水的主要病因有肝硬化、恶性肿瘤及结核性腹膜炎，约占90%，其中肝硬化占60%~85%，恶性肿瘤占5%~15%，结核性腹膜炎占1%~5%，其他少见的病因包括心源性腹水、低蛋白血症腹水、肾脏病等。许多临床研究表明，中药复方治疗肝硬化腹水能有效抑制病情的进展、改善临床症状，具有疗效明确、不良反应少等优点。现将近年来中药复方治疗肝硬化腹水的临床研究综述如下。
Liver cirrhosis is the end stage of various chronic liver diseases, mainly infected with hepatitis B virus (HBV). According to statistics, 257 million people are infected with HBV worldwide. Ascites is a common complication of liver cirrhosis, which indicates the progression of liver cirrhosis to decompensated stage, and its clinical prognosis is poor, with a mortality rate of 50% within 3 years. The main cause is liver cirrhosis, malignant ascites and tuberculous peritonitis, which accounts for about 90%, including cirrhosis accounted for 60%~85%, malignant tumor was 5%~15%, tuberculous peritonitis was 1%~5%, other rare causes include cardiac ascites, hypoalbuminemia ascites, kidney disease, etc. Many clinical studies have shown that Chinese traditional medicine compound treatment of cirrhosis ascites can effectively restrain the progress of the disease, improving clinical symptoms, and has the advantages of clear curative effect, less adverse reaction. This article reviews the clinical studies of traditional Chinese medicine compound in the treatment of liver cirrhosis ascites in recent years.